Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gastrointestinal tumors
Biotech
Cogent eyes FDA approval after clearing another ph. 3 hurdle
A combo including the company's tyrosine kinase inhibitor scored a 46% objective response rate, compared to 26% for monotherapy.
Darren Incorvaia
Nov 10, 2025 10:57am
Olympus forms GI robotics startup with Revival Healthcare
Jul 25, 2025 11:50am
Astellas aims for CLDN18.2 gold with $1.34B licensing deal
May 29, 2025 7:30pm
Cancer biotech Inspirna winding down
Apr 1, 2025 3:50am
ArriVent pays Lepu $47M for GI-focused preclinical ADC
Jan 22, 2025 7:15am
JPM25: M&A strategist GSK acquires IDRx for $1B upfront
Jan 13, 2025 2:00am
